Euan Reid
@euanreid.pharmsky.app
180 followers 230 following 140 posts
Pharmacist 🏴󠁧󠁢󠁳󠁣󠁴󠁿 #Pharmsky
Posts Media Videos Starter Packs
euanreid.pharmsky.app
Current estimates show that around two-thirds of Scottish adults are overweight, and one-third are living with obesity; disproportionately higher than other UK nations & among the highest compared to EU countries. Between 2025 & 2040, an estimated additional 118k female and 36k male cases of obesity
publichealthscot.bsky.social
New research from PHS, conducted in collaboration with Sciensano, projects a surge in the number of adult cases of excess weight in Scotland by 2040. 📈

Read more on our website⬇️
https://publichealthscotland.scot/news/2025/october/scale-of-obesity-challenge-in-scotland-highlighted-by-new-research/
euanreid.pharmsky.app
AN OVERVIEW OF THE SOCIAL DETERMINANTS OF HEALTH IN SCOTLAND: THE COLLABORATION
FOR HEALTH EQUITY IN SCOTLAND

www.instituteofhealthequity.org/resources-re...
Reposted by Euan Reid
who.int
WHO @who.int · 7h
Between 2018–2023, antibiotic resistance increased in over 40% of the pathogen–antibiotic combinations monitored, with an average annual rise of 5–15%.

Resistance is highest in the WHO South-East Asian & Eastern Mediterranean Regions, where 1 in 3 reported infections were resistant 👉 bit.ly/438Ta1u
Text reads “Antibiotic resistance is rising,” with an upward arrow and a “40%” warning icon. Below, a text box says: “Between 2018 and 2023, resistance increased in over 40% of the monitored pathogen–antibiotic combinations, with an annual rise of 5–15%.”
Reposted by Euan Reid
who.int
WHO @who.int · 1d
🚨Drug-resistant bacteria are becoming more dangerous.

Life-saving antibiotics are losing effectiveness, increasing infection risks & limiting treatment options.

Some resistant infections can only be treated with antibiotics that are costly, difficult to access, & often unavailable 👉 bit.ly/438Ta1u
Infographic images of various antibiotic pills. The text reads:
“Common infections now often require stronger, more expensive antibiotics.
In 2023:
 1 in 3 urinary tract infections
 1 in 15 gastrointestinal infections
 1 in 6 bloodstream infections
…were resistant to antibiotics.”

The design uses orange and black text on a light blue background with pill icons illustrating the statistics.
Reposted by Euan Reid
Reposted by Euan Reid
leadcoalition.bsky.social
Risk of stroke associated with risperidone in dementia with and without co-morbid cardiovascular disease: population-based matched cohort study www.cambridge.org/core/journal...

#Alzheimers #dementia #stroke #geriatrics #neurology #cardiology
Fig. 2
Kaplan–Meier plots depicting the cumulative incidence of stroke in matched controls and risperidone users. Blue dashed line indicates risperidone users. Shading represents 95% confidence intervals. CVD, cardiovascular disease.
euanreid.pharmsky.app
Quality prescribing strategy for respiratory conditions in Scotland: improving patient care and promoting environmental sustainability 🏴󠁧󠁢󠁳󠁣󠁴󠁿
#Pharmsky

academic.oup.com/ijpp/article...
euanreid.pharmsky.app
AGA Clinical Practice Guideline on Management of Gastroparesis
#Pharmsky

www.gastrojournal.org/article/S001...
Reposted by Euan Reid
thementalelf.bsky.social
Next up live at #CMHP25 we have Anita Solanki, Clinical Pharmacist and Menopause Specialist.

Menopause and Mental Health:
The Pharmacy Perspective.

I really hope she encourages more pharmacists and other clinicians to bring hormones into mental health conversations. It's about time!

THREAD 🧵
Reposted by Euan Reid
chrischirp.bsky.social
After a long pause, I've just done another England Covid & NHS update as we head into the autumn/winter season.

TLDR: we're in a significant Covid wave now, the NHS is stretched, get boosted if you're eligible.

christinapagel.substack.com/p/england-is...
England is now experiencing a significant Covid wave, after 10 months of relative quiet
The latest Covid situation in England and a look at where NHS services are as we head into winter
christinapagel.substack.com
Reposted by Euan Reid
tobycapstick.bsky.social
Important message for all people in the TB community
tb-alert.bsky.social
There is a UK national shortage of some anti-TB medicines, expected to last until at least the end of 2025. Please be reassured that plans are in place to protect your health. Please find out more at bit.ly/4o8s6Yk or contact TB Alert:
[email protected]
-https://healthunlocked.com/tb-alert
Reposted by Euan Reid
Reposted by Euan Reid
kbaillie.bsky.social
‼️Exciting Band 8a Job Opportunity to join our cancer care pharmacy team in NHS Lanarkshire
🔗 apply.jobs.scot.nhs.uk/Job/JobDetai...
🗓️Closing date is 22nd October
📲📧 Happy to chat to anyone interested / looking to find out more
looking for a job right now sign with magnifying glass
ALT: looking for a job right now sign with magnifying glass
media.tenor.com
euanreid.pharmsky.app
Empowering patients and upskilling clinicians to tackle overprescribing

#Pharmsky

thehealthinnovationnetwork.co.uk/news/empower...
The programme has successfully engaged with over 12,000 healthcare professionals to support them with the skills and confidence to tackle overprescribing, delivered 124 communities of practice across the country, and co-developed vital resources to empower patients in conversations about their medicines.
The programme was launched in April 2022 to address the urgent and growing challenge of problematic polypharmacy – when a patient is taking multiple medicines, some of which may no longer be necessary or could be causing harm.
The scale of the issue is considerable. In March 2025, more than 718,000 people aged 65 and over in England were taking 10 or more medicines, a figure projected to exceed 1.1 million by 2035 without effective intervention.
To address this, the programme, which engaged all 42 Integrated Care Boards (ICBs) across England, was built on a core three-pillar approach:
Population health management: using NHS data to identify patients most at risk of harm from their medicines.
Education and training: upskilling the primary care workforce to confidently and safely stop unnecessary medicines.
Changing public behaviour: co-producing resources to support patients in having better, shared-decision-making conversations about their medicines.
A range of Polypharmacy education and learning events reached 12,891 health and care professionals, including 1,301 GPs and pharmacists who completed the Polypharmacy Action Learning Sets (ALS) course, which has been exceptionally well-received:
99% of ALS participants said they would recommend the course to colleagues.
83% reported making changes to their practice as a result, including increasing shared decision-making with patients and actively stopping medicines.
Participants highly valued the interactive, peer-to-peer discussions and specialist input, particularly from geriatricians. One GP described the course as transformative, saying: “This will change my practice more than any learning event I have ever done.”
euanreid.pharmsky.app
Five years of a greener NHS: progress and forward look.

"NHS Carbon Footprint emissions have already decreased by 14% since the strategy to deliver a net zero NHS was published, and over 68% since 1990".

#Pharmsky #Medsky

www.england.nhs.uk/long-read/fi...
In 2020, the NHS became the first healthcare system in the world to commit to becoming net zero.

This commitment was made in response to the evidence that climate change is no longer a distant threat but is already affecting the health and wellbeing of patients and communities across the country.

The benefits of taking action not only reduce the future impacts of climate change, but also deliver more immediate benefits for health.

Such action sits alongside the urgent need to adapt the NHS to the impacts of climate change, which will be felt hardest by the most vulnerable in our society, and will place significant strain on NHS infrastructure, staff and finances.

Healthcare in England is estimated to contribute between 4% and 5% of national emissions, and around 40% of all emissions generated by the public sector.

Not only does the NHS have a clear responsibility to minimise its environmental impact, building a more sustainable NHS offers a unique opportunity to deliver better patient care while minimising cost and impact on future services.

NHS England committed to regular reviews of progress, and this report is the first assessment.

To support this work, the NHS Net Zero Expert Panel – comprising global leaders and specialists in environmental sustainability, healthcare and carbon analytics – was convened to provide guidance on the next stages of this critical journey.

Despite the challenges over recent years, NHS staff have demonstrated extraordinary dedication. They have embraced sustainability principles, implemented impactful solutions and driven change.

Thanks to their efforts, NHS Carbon Footprint emissions have already decreased by 14% since the strategy to deliver a net zero NHS was published, and over 68% since 1990 – an impressive achievement given the context, and a reflection of their commitment.
Reposted by Euan Reid
nejm.org
In patients with acute ischemic stroke treated with intravenous thrombolysis, early tirofiban improved functional outcomes at 90 days. Intracranial hemorrhage was uncommon but more frequent with tirofiban. Full ASSET-IT phase 3 trial results and Research Summary: nej.md/44nYCNS

#MedSky
The New England Journal of Medicine                   
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke 
A Research Summary based on Tao C et al. | 10.1056/NEJMoa2503678 | Published on July 4, 2025 

Visual representations of the patients in the trial and the treatments they were assigned.                       

Read the full Research Summary at NEJM.org.
Reposted by Euan Reid
patientsafetylearning.org
There is a currently shortage of Creon, a pancreatic enzyme replacement therapy, which is expected to last until 2026. In this blog Sophie tells us about her experience of trying to get hold of Creon and the challenges she has faced. www.pslhub.org/learn/patien... #patientsafety
Creon shortages: “It’s just another thing patients with cystic fibrosis could do without”
Sophie, a patient with cystic fibrosis, tells us about her experience of trying to get hold of Creon and the challenges she has faced
www.pslhub.org
Reposted by Euan Reid
patientsafetylearning.org
🧵Shared Decision Making🧵

(1/10) Featured on the hub today, a selection of decision support tools designed to assist shared decision making between patients and clinicians. #patientsafety
An image of four NHS decision support documents overlapping each other that are titled as follows: Making a decision about stable angina, Making a decision about Open-angle glaucoma, Making a decision about managing heavy periods, Making a decision about enlarged prostate (BPE).
Reposted by Euan Reid
jscottuob.bsky.social
Here is a new paper from our team looking at motivations for co-use of benzodiazepines and opioids. Highlights the big gaps in access to appropriate mental health care. @capcbristol.bsky.social
link.springer.com/article/10.1...
Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study - Harm Reduction Journal
Background Drug-related deaths have substantially increased over the past decade in the UK, particularly in Scotland. Co-use of opioids and benzodiazepines (prescribed and/or illicit) is contributing to rising mortality. This study identified motivations in people’s co-use with the aim of informing prescribing and harm reduction interventions to address drug-related deaths. Methods We interviewed 48 people who co-use opioids and benzodiazepines and/or z-drugs (zopiclone and zolpidem) in Glasgow (n = 28), Teesside (n = 10) and Bristol (n = 10). Most participants self-identified as male (n = 37, 77%), white (n = 45, 94%) and had a mean age of 43 years (range: 25–61 years). The majority reported at least one overdose experience, and poor mental health including trauma. Interviews were semi-structured, conducted by an academic and/or peer researcher, and analysed using reflexive thematic analysis. Results Participants’ motivations for co-using mapped onto two interlinked meta-themes: (1) Functional motivations included co-using to augment drug effects, self-medicate or help to generate income. (2) Experiential motivations described participants’ desires to achieve a ‘buzz’ (feeling energised), ‘glow’ (feeling comforted), ‘oblivion’ (escaping trauma and adversity), and ‘gouching’ (physical and mental sensations of ebbing in and out of glow and oblivion). Functional and experiential motivations were dynamic, interrelated and often co-occurred. Conclusions The importance of assessing motivations to co-use should be routinely recognised as part of harm reduction and medication assisted treatments to reduce mortality risk.
link.springer.com
Reposted by Euan Reid
nejm.org
In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo
The New England Journal of Medicine                   
Apixaban for Extended Treatment of Provoked Venous Thromboembolism 
A Research Summary based on Piazza G et al. | 10.1056/NEJMoa2509426 | Published on August 30, 2025 

Visual representations of the patients in the trial and the treatments they were assigned.                       

Read the full Research Summary at NEJM.org.
Reposted by Euan Reid
oxprimarycare.bsky.social
Black African women are almost 6x less likely to get HRT than white women in England – and women in the most deprived areas are half as likely as those in the most affluent.

Major Oxford study of 2m women reveals stark inequalities in menopause care.

From @drjenny-hirst.bsky.social and team
Major study reveals stark HRT inequalities across England
Women from Black African backgrounds almost six times less likely to receive hormone replacement therapy than white women, new department-led research finds
www.phc.ox.ac.uk
Reposted by Euan Reid
healthimprovescot.bsky.social
Paracetamol remains safe to use during pregnancy, confirms MHRA, RCOG and BUMPS.

SIGN, part of our organisation, supports evidence-based practice to improve care across Scotland.

Read the full statement, link in comments:
A photo of a box of paracetamol tablets, with a graphic of the Healthcare Improvement Scotland logo, and the words "Paracetamol in pregnancy"